The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial.

1: PLoS Clin Trials. 2007 May 18;2(5):e19.

The GK, Bleijenberg G, van der Meer JW.

Department of General Internal Medicine, Nijmegen Expert Centre Chronic Fatigue, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.

OBJECTIVES: It is unclear whether insulin-like growth factor (IGF) function is involved in the pathophysiology of chronic fatigue syndrome (CFS). Unpublished data and reports in patient organization newsletters suggest that Acclydine, a food supplement, could be effective in the treatment of CFS by increasing biologically active IGF1 levels. Here we aimed to measure the IGF1 and IGF binding protein (IGFBP) 3 status of CFS patients compared to age- and gender-matched neighborhood controls, and to assess the effect of Acclydine on fatigue severity, functional impairment, and biologically active IGF1 level (IGFBP3/IGF1 ratio).

DESIGN: A randomized, placebo-controlled, double-blind clinical trial. SETTING: Radboud University Nijmegen Medical Centre, The Netherlands. PARTICIPANTS: Fifty-seven adult patients who fulfilled the US Centers for Disease Control and Prevention criteria for CFS. IGF status of 22 CFS patients was compared to that of 22 healthy age- and gender-matched neighborhood control individuals.

INTERVENTION: Acclydine or placebo for 14 wk.

OUTCOME MEASURES: Outcomes were fatigue severity (Checklist Individual Strength, subscale fatigue severity [CIS-fatigue]), functional impairment (Sickness Impact Profile-8 [SIP-8]), and biologically active IGF1 serum concentrations. Analyses were on an intention-to-treat basis.

RESULTS: There was no difference in IGF status in 22 CFS patients compared to healthy age- and gender-matched control individuals. Treatment with Acclydine did not result in significant differences compared with the placebo group on any of the outcome measures: CIS-fatigue +1.1 (95% CI -4.4 to +6.5, p = 0.70), SIP-8 +59.1 (95% CI -201.7 to +319.8, p = 0.65), and IGFBP3/IGF1 ratio -0.5 (95% CI -2.8 to +1.7, p = 0.63).

CONCLUSION: We found no differences in IGF1 status in CFS patients compared to healthy matched neighborhood controls. In addition, the results of this clinical trial do not demonstrate any benefit of Acclydine over placebo in the treatment of CFS.

PMID: 17525791 [PubMed – in process]

FMS Global News

Tenderpoints

Advertisements

About FMS Global News

Folllowing Rick Usher's death in December 2008, at his request in September of that year, I had agreed, as his principal contributor and an experienced journalist, to run the FMS Global News service due to his heavy commitments to music and raising research funds through this avenue. Following his sad and sudden death I hope to continue his work as he would have wished.
This entry was posted in Article, Autoimmune Diseases, Awareness, Britain, Chronic Fatigue, Chronic Fatigue Syndrome, Chronic Insomnia, Chronic Multisymptom Illness, Chronic Myofacial Pain, Chronic Pain, Chronic Pain Disorders, Chronic Widespread Pain, Clinical, Clinical Pain, Clinical Trials, Diseases, Dysfunctional Pain Processing, Europe, Fatigue, Feeds, Fibrohugs, Fibrohugs News, Fibromyalgia, Fibromyalgia Blogs, Fibromyalgia News, Fibromyalgia News Belgium, Fibromyalgia News Deutschland, Fibromyalgia News France, Fibromyalgia News Israel, Fibromyalgia News Italy, Fibromyalgia News Japan, Fibromyalgia News Jerusalem, Fibromyalgia News Korea, Fibromyalgia News Southeast Asia, Fibromyalgia News Turkey, Fibromyalgia News Wisconsin, Fibromyalgia Press Releases, Fibromyalia News Germany, FMS Global News, Global News, Health, Health Care, Health Insurance, Healthcare Quality, Hypersensitivity, Invisible Illness, Invisible Illnesses, Medical, Medical Insurance, Medical Journals, Medical Research, Medical University, Multiple Chemical Sensitivity, Myofacial Pain Syndrome, News, News Australia, News Belgium, News Canada, News France, News India, News Ireland, News Israel, News Italy, News Japan, News Jerusalem, News Korea, News Montreal, News Nigeria, News Norway, News Quebec, News Saskatchewan, News Scotland, News Southeast Asia, News Spain, News Sweden, News Toronto, News Turkey, News UK, News Wisconsin, Nigeria, North Carolina, Ontario, Pain, Pain Management, Pain Matrix, Philadelphia, Poor Sleep, Preventive Medicine, Rehabilitation, Research, RSS, Sleep Disorders, Sleep Disturbance, Sleep Quality, Statistics, Stockholm, Tenderpoints, The Netherlands., Therapies, Toronto, Universities, US, Virginia, Washington DC, World, World News. Bookmark the permalink.

One Response to The effect of acclydine in chronic fatigue syndrome: a randomized controlled trial.

  1. Pingback: Daily Press Summary 04/06/2007 « Action for M.E.

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s